Compare VANI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VANI | ADVB |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 109.2M |
| IPO Year | 2014 | N/A |
| Metric | VANI | ADVB |
|---|---|---|
| Price | $1.23 | $4.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 321.7K | 129.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.19 |
| 52 Week High | $1.92 | $5.69 |
| Indicator | VANI | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 88.92 |
| Support Level | $1.17 | $0.41 |
| Resistance Level | $1.24 | N/A |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.00 | 0.41 |
| Stochastic Oscillator | 38.89 | 70.43 |
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.